SparingVision Reports Positive Initial Safety Data from the

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

France , Paris , France General , United States , Boissel , Rhôalpes , Amber Fennell , Avril Daly , Davide Salvi , Namrata Taak , Nathalie Trepo , Joseph Martel , University Of Pittsburgh Medical Center , Consilium Strategic Communications , National Hospital , Linkedin , Eye Center , Paris Vision Institute , Rd Fund , Retina International , Sparingvision The Company , Vision Reports Positive Initial Safety Data , Data Safety Monitoring Board , Chief Executive Officer , Recommended Doses , Isabelle Audo , Pittsburgh Medical Center , Cone Viability Factor , Cone Viability Factor Long , Age Related Macular Degeneration , Alain Sahel , Paris Vision , Jose Alain Sahel , Retinitis Pigmentosa , Intellia Therapeutics , Adbio Partners , Fondation Voir , Jeito Capital ,